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Abstract
Substantial improvements have been made in recent years in the ability to engraft human cells and tissues into
immunodeficient mice. The use of human hematopoietic stem cells (HSCs) leads to multi-lineage human
hematopoiesis accompanied by production of a variety of human immune cell types. Population of murine primary
and secondary lymphoid organs with human cells occurs, and long-term engraftment has been achieved.
Engrafted cells are capable of producing human innate and adaptive immune responses, making these models the
most physiologically relevant humanized animal models to date. New models have been successfully infected by a
variety of strains of Human Immunodeficiency Virus Type 1 (HIV-1), accompanied by virus replication in lymphoid
and non-lymphoid organs, including the gut-associated lymphoid tissue, the male and female reproductive tracts,
and the brain. Multiple forms of virus-induced pathogenesis are present, and human T cell and antibody responses
to HIV-1 are detected. These humanized mice are susceptible to a high rate of rectal and vaginal transmission of
HIV-1 across an intact epithelium, indicating the potential to study vaccines and microbicides. Antiviral drugs,
siRNAs, and hematopoietic stem cell gene therapy strategies have all been shown to be effective at reducing viral
load and preventing or reversing helper T cell loss in humanized mice, indicating that they will serve as an
important preclinical model to study new therapeutic modalities. HIV-1 has also been shown to evolve in response
to selective pressures in humanized mice, thus showing that the model will be useful to study and/or predict viral
evolution in response to drug or immune pressures. The purpose of this review is to summarize the findings
reported to date on all new humanized mouse models (those transplanted with human HSCs) in regards to HIV-1
sexual transmission, pathogenesis, anti-HIV-1 immune responses, viral evolution, pre- and post-exposure
prophylaxis, and gene therapeutic strategies.
Review
Introduction to humanized mice
Humanized mice have allowed for extensive study of the
development and function of the human immune sys-
tem. Soon after their inception, the SCID-hu thy/liv [1]
and SCID-hu-PBL [2] models (pioneered by McCune
and Mosier, respectively) were shown to support infec-
tion of pathogens that replicate in human immune cells.
In particular, Human Immunodeficiency Virus Type 1
(HIV-1) infection has been studied in great detail for
over two decades in humanized mice, largely due to the
expense involved with the use of non-human primates
and key differences between HIV-1 infection in humans
and chimpanzees. HIV-1 infection of humanized mice
has yielded valuable data ranging from the fields of in
vivo pathogenesis to drug efficacy and passive immunity.
However, there are caveats in the original humanized
mouse models: only a limited hematopoietic repertoire
was engrafted which varied by model, HIV-1 infections
were often short-term, and no primary adaptive immune
response was mounted against HIV-1 [3-6]. Thus, these
models provided data on acute HIV-1 infection of lim-
ited cell types and virtually unopposed by a host
immune response.
Recent advances in the production of profoundly
immunodeficient mouse strains have resulted in
improved human cell engraftment relative to the origi-
nal SCID-hu thy/liv and SCID-hu-PBL models [1,2].
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original humanized mouse models can spontaneously
generate murine T and B cells as animals age (leakiness)
and has high levels of natural killer (NK) cell activity,
both of which prevent efficient/prolonged xenoengraft-
ment [7]. Improvements in the available immunodefi-
cient mouse strains and the use of human CD34
+
hematopoietic stem cells (HSCs) have resulted in
improved, long-term engraftment of a variety of human
hematopoietic cell types as well as the ability to generate
primary human immune responses [8].
Mice deficient in the recombinase activating genes 1
and 2 (Rag1 and Rag2, respectively) do not exhibit leaky
production of T and B lymphocytes. The immune phe-
notypes in Rag1
-/- and Rag2
-/- strains are similar [9,10].
However, Rag-deficient animals produce normal levels
of NK cells, and thus additional mutations are required
in order to produce animals better suited for xenoen-
graftment studies. The non-obese diabetic (NOD) SCID
mouse is commonly used because the Prkdc mutation
prevents formation of mature T and B lymphocytes
while the NOD mutation results in a reduction of NK
cell activity [11]. However, it should be noted that a
major disadvantage of the NOD strain is a high inci-
dence of spontaneous thymic lymphomas which results
in a shortened lifespan [12]. The common gamma chain
receptor (gc, also referred to as the IL-2 receptor
g a m m ac h a i n )i sac o m p o n e n to ft h eI L - 2 ,I L - 4 ,I L - 7 ,
IL-9, IL-15, and IL-21 receptors and is the gene involved
in X-linked SCID [13]. The addition of the gc mutation
to the Rag1, Rag2, and NOD/SCID backgrounds further
blocks T and B cell development due to a lack of IL-2
signaling and also prevents maturation and expansion of
NK cells via a lack of IL-15 signaling [14,15]. Since
Prkdc
-/- (SCID) animals can experience leaky production
of T and B cells, the gc mutation is useful as a second-
ary means to block maturation of these cells. Nearly all
current humanized mouse models use gc
-/- animals,
with the exception being NOD/SCID animals which are
used for either HSC engraftment or to produce the BLT
model (see below). It should be noted that there are two
different gc mutations commonly in use for production
of humanized mice. One is a null mutation [16], and the
other is a truncation of the cytoplasmic signaling
domain [14]. It is currently unclear if there are func-
tional differences between these two mutations, since
both are expected to block signaling. In combination
with the NOD/SCID mutation, these mouse strains are
commonly referred to as NOG (truncation) and NSG
(knockout) mice.
Combinations of the above mutations thus far ana-
lyzed for human hematopoietic stem cell engraftment
have included such strains as Rag2
-/-gc
-/-,N O D / S C I D ,
NOD/SCIDgc
-/-,R a g 1
-/-gc
-/-,N O D / R a g 1
-/-gc
-/-,a n d
NOD/SCIDb2m
-/- mice [17-23]. When engrafted with
hematopoietic stem cells, these immunocompromised
strains have shown the most effective xenoengraftment
observed to date, in terms of the spectrum of human
cells produced, the penetration of human cells into var-
ious organs, the duration of engraftment, and the ability
to generate primary human adaptive immune responses
[8]. All of the major HIV-1 target cells, including
human CD4
+ T cells, monocytes, macrophages, and
dendritic cells are readily detected in these humanized
mice. A detailed review of how to generate humanized
Rag2
-/-gc
-/- mice is available [24], and methods to pre-
pare humanized NOD/SCIDgc
-/- mice and humanized
Rag1
-/-gc
-/- mice are very similar. It should be noted
that the methods used to prepare human HSCs and to
inject animals with grafts are relatively straightforward
and in many cases require a simple, intrahepatic or
intravenous injection. The BLT model (bone marrow,
liver, thymus) engrafts NOD/SCID or NOD/SCIDgc
-/-
mice with a combination of human fetal liver and thy-
mic tissue (the SCID-hu thy/liv model) followed by a
CD34
+ cell graft. As a result of the relatively simple
techniques needed to generate humanized mice, many
new laboratories are adopting these models.
Viral infections in humanized mice
Improved and prolonged human cell engraftment has
generated renewed interest in the study of human
pathogens of the immune system in the hopes that pre-
vious problems have been solved (see first paragraph).
To date, the newer humanized mouse models have been
examined for infection by a variety of human viruses
including the retroviruses HIV-1 (subject of this review)
and HTLV-1 [25]; the herpesviruses EBV [17,26-30],
KSHV [31,32], hCMV [33], and HSV-2 [34]; Dengue
virus [35,36]; and recombinant adenovirus [37]. An
adaptation using human liver transplants has also been
described [38,39] which can be infected with HBV and
HCV [40,41]. A summary of all viral pathogens and
other immunogens studied thus far in the new genera-
tion of humanized mice is provided in Table 1.
One of the most exciting developments for the new
generation of humanized mice is the generation of pri-
mary human adaptive immune responses following
infection or immunization with a variety of pathogens.
T cell responses have been demonstrated against HIV-1,
EBV, toxic shock syndrome toxin 1, and a recombinant
adenoviral vector expressing HCV proteins
[17,28-30,37,42], while B cell responses have been docu-
mented against HIV-1, Dengue virus, tetanus toxoid,
KSHV, HSV-2, and the haemophilus influenzae B conju-
gate vaccine [17,32,34,35,42-46]. Antigen-specific anti-
body class-switching and detection of neutralizing
antibody responses following Dengue virus infection
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response generated in these new and improved models
[35,47].
Humanized mouse models and HIV-1 strains used to
infect them
To date, six different mouse strains humanized with
human HSCs have been analyzed for HIV-1 infection,
including Balb/c Rag2
-/-gc
-/- mice (RAG-hu) humanized
with purified CD34
+ HSCs derived from umbilical cord
blood [44,48-53], from fetal liver [48,49,54-64] or from a
non-specified source [65]; NOD/SCID gc
-/- (hNOG or
hNSG) mice humanized with cord blood derived CD34
+
cells [43,66-75]; hNOG or hNSG mice humanized with
fetal liver derived CD34
+ cells [76]; NOD/SCID BLT
mice [42,45,77-80], hNSG BLT mice [42,81], and Balb/c
Rag1
-/-gc
-/- mice humanized with purified CD34
+ HSCs
from human fetal liver [23]. One report has shown suc-
cessful engraftment and HIV-1 infection in C57BL/10
Rag2
-/-gc
-/- mice engrafted with non-purified human
fetal liver cells [64], although another report has shown
an inability to achieve usable engraftment in the related
C57BL/6 Rag2
-/-gc
-/- strain [34]. Two reports examining
RNA interference strategies against HIV-1 have used ex
vivo infections of humanized mouse-derived cells
[60,79].
A large variety of HIV-1 isolates have been examined
for infection in the new humanized mouse strains,
although most work has been performed with molecular
clones of the virus. The following CCR5 tropic strains
have been reported: JR-CSF [42,43,48,49,52,53,
59,64-68,72,77,78], BaL-1 [23,55,57,62,69,70,74], YU-2
[44,48,51], ADA [46,71,75,76], NFN-SX(SL9) [58,79],
1157 [46], a vif-deficient strain of JR-CSF [73], and the
Table 1 Viruses and other immunogens studied in the new generation of humanized mice
Infecting Agent Humanized mouse model References
Viruses:
HIV-1 Rag2-/-gc-/- [44,46,48-51,55-61,63-65]
HIV-1 NOD/SCIDgc-/- (hNOG) [43,66,67,72,73]
HIV-1 NOD/SCIDgc-/- (hNSG) [68-71,74-76]
HIV-1 NOD/SCID BLT [42,45,77-79]
HIV-1 NOD/SCIDgc-/- (hNSG) BLT [42,81]
HIV-1 Rag1-/-gc-/- [23]
HTLV NOD/SCID [25]
EBV Rag2-/-gc-/- [17,122]
EBV NOD/SCIDgc-/- (hNOG) [27,28]
EBV NOD/SCIDgc-/- (hNSG) [29]
EBV NOD/SCID BLT [30]
EBV NOD/SCID [26]
KSHV NOD/SCID [31,32]
Dengue Virus Rag2-/-gc-/- [35]
Dengue Virus NOD/SCID [36]
HSV-2 Rag2-/-gc-/- [34]
rAd-HCV NOD/SCIDgc-/- (hNSG) [37]
hCMV NOD/SCIDgc-/- (hNSG) [33]
HCV Rag2-/-gc-/-Fah-/- [40]
HBV Rag2-/-gc-/-Fah-/- [40]
HBV Rag2-/-gc-/-uPa-/- [123]
Bacteria:
Salmonella typhi Rag2-/-gc-/- [124]
Non-infectious agents:
Tetanus toxoid Rag2-/-gc-/- [17,97]
Haemophilus influenza B conjugate vaccine Rag2-/-gc-/- [46]
Hepatitis B surface antigen vaccine Rag2-/-gc-/- [97]
Toxic shock syndrome toxin 1 NOD/SCID BLT [30]
2,4-dinitrophenyl hapten-keyhole limpet hemocyanin NOD/SCID BLT [47]
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BaL-1 env sequence [70]. The following CXCR4 tropic
strains have been studied: NL4-3 [23,44,48,49,54,
55,57,67,72,79], LAI [45], MNp [67], a variant of NL4-3
with GFP inserted (NLENG1-IRES) [57], and LAI with a
V38E mutation in gp41 [80]. The following dual-tropic
strains have additionally been analyzed for infection:
HIV-R3A [49,61,63] and 89.6 [48]. One study has used a
chimeric Simian Immunodeficiency Virus encoding the
envelope gene from the dual-tropic HIV-1 strain 89.6
(SHIV-C2/1) [43]. Finally, primary isolates (not molecu-
lar clones) from subtype B (strain UG 209A) and sub-
type C (strain 1157) have also been examined in RAG-
hu mice, although UG 209A was only tested in mice
humanized with human PBLs. It is clear from the results
that HSC-humanized mice are susceptible to a broad
variety of HIV-1 strains. Further work should involve
diverse primary isolates of HIV-1, especially when the
efficacy of vaccination is under examination. Since virus
stocks derived from molecular clones are identical or
nearly identical in genomic sequence, the ability to
block viral transmission is predicted to be much simpler
as compared to the natural scenario in humans where
exposure is to multiple genetically distinct isolates [82].
Additionally, little work has been done using mutant
strains of HIV-1 to discover the contribution of various
genes to pathogenesis, although the few reports to do so
are summarized herein.
W ea r en o ta w a r eo fa n ys t u d i e st h a th a v ee x a m i n e d
the minimum level of human cell engraftment required
to achieve consistent HIV-1 infection, although in our
hands we have found that an animal with as low as 5%
peripheral blood engraftment (5% hCD45
+, 95%
mCD45
+) can be infected by intraperitoneal injection
[57]. A minimal dose of virus required to infect huma-
nized mice has also not been established, although
unsuccessful infections using direct injection routes with
low doses of HIV-1 (100-500 TCID50) have been
reported [46,58]. 1 ng of p24 was sufficient to infect all
RAG-hu animals in two studies from the same group
[49,61]. For nearly all studies the goal has been to achieve
successful viral replication in vivo and the impact (if any)
of the infectious dose has not been explored, despite a
large range of doses studied ranging from 10
2 TCID50
[46] or 1 ng p24 [49,61] to 2 × 10
6 TCID50 or 400 ng
p24. Mucosal transmission has been achieved with a dose
as low as 156 TCID50 in RAG-hu mice or 170 ng p24 in
BLT mice. When molecular clones of the virus are used
for infections, the impact of the infectious dose may not
be as critical to many experiments as compared to a
highly diverse population. Since engraftment levels vary
from one animal to another and infection routes differ by
study, it is not anticipated that a uniform minimal dose
will apply to all animals or to all engraftment models.
Routes of viral infection
Various routes of viral exposure have been tested in
humanized mice. Direct routes such as intravenous
[43,49,59,61,64,65,67,78], intraperitoneal [42,44,50,51,
57,58,64,66,69,71,72] and intrasplenic [64] injections
have been used extensively and result in a very high effi-
ciency of infection. In addition, mucosal engraftment of
human HIV-1 target cells has been documented; also,
mucosal transmission of CCR5 tropic viruses across an
intact epithelium has been found in both the BLT and
RAG-hu models. Abrasions have been used for rectal
transmission in BLT mice [45,78], possibly to mimic
rectal intercourse, but abrasions are not required for
rectal transmission in RAG-hu mice [55]. Abrasions are
not necessary for vaginal transmission in BLT mice [77],
RAG-hu mice [55], or humanized Rag1
-/-gc
-/- mice [23].
We have previously shown successful mucosal transmis-
sion in RAG-hu mice for both CCR5 tropic and CXCR4
tropic strains introduced both vaginally and rectally,
although a lower rate of infection was observed with
CXCR4 strains which are not effectively transmitted
sexually in humans [55].
It should be noted that poor intestinal engraftment
and only rare HIV-1 rectal transmission in RAG-hu
mice were reported by Hofer et al.[ 4 8 ] .A d d i t i o n a l
reports have shown mucosal engraftment in RAG-hu
mice [34,59] and HSC-engrafted hNSG mice [74]. These
findings indicate that simple HSC engraftment is suffi-
cient to achieve mucosal engraftment as compared to
the thymic implants required for the BLT model. In
addition, HIV-1 nucleic acids were detected in the rec-
tum, small intestine, and uterus of infected hNOG mice
[67], although it is not clear if this is due to the pre-
sence of blood cells in non-perfused mice. Other reports
have shown successful vaginal HIV-1 transmission in
RAG-hu mice without examining mucosal engraftment
[62,83]. Finally, in our recent work with humanized
Rag1
-/-gc
-/- mice we have also detected successful vagi-
nal transmission of HIV-1 [23]. These data indicate that
mucosal engraftment and HIV-1 transmission are possi-
ble in a wide variety of mouse strains, and that simple
HSC implants are sufficient (as compared to thymic
implants plus HSC implants in BLT mice).
The reasons for the discrepancy in detection of human
cell engraftment in the mucosa of humanized mice and/
or differences in HIV-1 transmission rates are still
unclear. However, several variables between the various
experiments could suggest possible explanations for dif-
fering results. These include the source of cells (fetal liver
vs. cord blood), the strains of mice used, cytokine-
mediated expansion of HSCs, analysis of vaginal vs. rectal
engraftment/transmission, and the use of antibiotics for
mouse maintenance. First, some papers that have ana-
lyzed mucosal engraftment and/or HIV-1 transmission
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fetal livers [23,45,55,59,62,77,78,83] as sources of HSCs;
two papers have examined both types of cells [48,59].
Since fetal liver cells are more primitive than cord blood
cells (they are taken from pre-term samples and cord
blood is taken from full-term samples), it is possible that
they have a greater capacity for repopulation, differentia-
tion, and organ penetration. It is clear that the use of
fetal liver cells results in mucosal engraftment [45,55,77]
and mucosal HIV-1 transmission [23,55,62,77,78,83]. The
data for cord blood cells are not as clear. Holt et al.u s e d
cord blood cells in hNOG mice and frequently detected
human cell engraftment in the large and small intestines
(including CD4
+ T cells) but did not attempt mucosal
transmission [74]. It is important to note that Holt et al.
used cytokines to mediate HSC expansion in preparation
for nucleofection. It has been suggested that cytokine-
mediated expansion of HSCs may explain the differing
levels of mucosal engraftment [59]. The putative
mechanism of this hypothesis is that the use of cytokines
modifies the properties of HSCs, thereby giving them an
increased potential for differentiation and penetration
into mucosal tissues. The report by Hofer et al. analyzed
rectal and intestinal tissues and used either fetal liver or
cord blood cells as HSCs, but detected little engraftment
and only rarely achieved rectal transmission [48]. No
cytokines were used to expand either type of cell. The
use of cytokines to expand HSCs is thus a critical differ-
ence between the methods used by Hofer et al.a n d
others. Choudhary et al. used fetal liver cells and also cul-
tured HSCs in the presence of cytokines and detected
significant intestinal engraftment in 2 of 6 mice [59].
Papers from the Akkina group have all used fetal liver
cells and cytokine expansion [23,55,62,83]. Kwant-Mitch-
ell et al.u s e dc o r db l o o dc e l l st h a tw e r en o te x p a n d e d
with cytokines and only detected mucosal engraftment
after vaccination with attenuated HSV-2 [34]. A recent
study indicates that engraftment of the peripheral blood,
lymph nodes, spleen, and bone marrow of RAG-hu mice
is significantly higher after culturing HSCs in the pre-
sence of cytokines versus immediate transplantation of
uncultured cells [84]. Serum IgG levels are also signifi-
cantly higher, although IgM levels were not [84]. This
study supports the hypothesis that culturing HSCs in the
presence of cytokines prior to engraftment leads to sig-
nificantly better engraftment as assessed by multiple end-
points, but no analysis was made of mucosal
engraftment. Thus, it appears that the use of cytokines to
expand HSCs may be critical to achieving mucosal
engraftment, even more so than the use of fetal liver cells.
The mouse strain used does not appear to make a dif-
ference in the ability to achieve mucosal engraftment or
HIV-1 mucosal transmission with the data currently
available. Mucosal engraftment has been detected in
NOD/SCID BLT mice [45,77], Rag2
-/-gc
-/- mice
[34,55,59], and hNOG mice [74] while HIV-1 mucosal
transmission has been detected in NOD/SCID BLT
mice [45,77,78], Rag2
-/-gc
-/- mice [55,62,83], and Rag1
-/-
gc
-/- mice [23]. Interpretations of mucosal engraftment
and susceptibility to infection should also recognize that
vaginal and rectal/intestinal engraftment cannot be
directly compared. Hofer et al. focused their study on
rectal engraftment in RAG-hu mice and did not exam-
ine vaginal engraftment and transmission. Of the studies
to emerge from the Akkina lab, only one examined rec-
tal engraftment and transmission [55] while most stu-
dies have focused on vaginal transmission [23,55,62,83]
w i t has i n g l er e p o r tt h a te v a l u a t e dv a g i n a le n g r a f t m e n t
[55]. While we are confident in our ability to achieve
rectal engraftment and transmission, the sample size of
our vaginal challenge experiments is much higher and
vaginal engraftment and transmission were not exam-
ined by Hofer et al.
A final point to consider is the status of the normal
microbial flora of the humanized mouse rectum and
intestinal tract. Humanized mice are sometimes housed
on a regimen of antibiotics in their drinking water in
order to prevent bacterial infections that are common in
highly immunodeficient mice. It is possible that various
mouse colonies are maintained with different antibiotics
and/or concentrations of antibiotics, or no antibiotics at
all, thus leading to differences in the bacteria present in
the gut. The flora present (or lacking) in various colo-
nies may influence the ability and/or tendency of human
immune cells to traffic to mucosal sites.
HIV-1 viremia
Viremia in HSC-humanized mice is usually detectable
by 1 week post-infection, which often represents the
first time point analyzed. The most sensitive means to
detective viremia is quantitative PCR (Q-PCR), since
comparable studies using p24 ELISA have shown an
inability to detect viremia at various time points post-
infection [46,50,58] whereas Q-PCR shows consistent
detection [44,56]. The mean peak viremia for CXCR4
virus is approaching 10
7 viral genomes per ml of plasma
while the mean peak viremia for CCR5 virus is around
10
6 viral genomes per ml of plasma [43-45,50,53,55,
56,67,72,75,77,78]. Peak viremia typically occurs in the
range of 1-2 months post-infection [23,44,45,53,55,
56,67,72,74]; however, CD4
+ T cell loss in the blood is
more severe with CXCR4 virus and the decrease in tar-
get cells is accompanied by a decrease in viremia
[23,44,56]. CCR5 tropic virus maintains a higher level of
viremia for sustained periods which correlates with
decreased levels of target cell loss over time. The peak
level of viremia, both in terms of kinetics and levels, is
similar for all routes of infection and no significant
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The impact of viral dose on subsequent viral loads is
still unclear due to the presence of multiple variables
between experiments, including methods used to titer
virus stocks. However, animals infected by mucosal
transmission tend to show sporadic detection of viremia
for the first weeks of infection [23,45,77,78]. We have
s h o w nt h a tH I V - 1i n f e c t i o ni nR A G - h um i c ec a nb e
sustained for over a year post-infection with either
CCR5 tropic or CXCR4 tropic virus. We detected vire-
mia for up to 63 weeks and HIV-1 RNA by in situ
hybridization for up to 67 weeks post-infection [56].
Some groups have reported a drop to undetectable
levels of viral load for multiple time points, but this is a
rare finding occurring in few mice [44,72]. Most reports
consistently detect all infected animals to be positive
[23,55-57,67,78,85]. Thus, not only is human cell
engraftment a life-long condition in HSC-humanized
mice, but productive HIV-1 infection is also maintained
for the same period. Since many HIV-1-associated dis-
eases take time to develop, it is important that these
models sustain long-term infections.
Sites of virus replication
The distribution of HIV-1 replication in humanized
mice has been analyzed by many independent groups
using immunohistochemical and in situ hybridization
techniques to detect HIV-1 proteins and genomes/gene
expression, respectively. The most prominent organs
that feature HIV-1 replication in humans are also highly
positive for HIV-1 replication in humanized mice,
namely the spleen [42-46,49,52,55,57,72,77,78], lymph
nodes [42-46,49,55,56,71,72,77], and thymus
[44,49,55,57]. The thymic organoid graft of BLT mice is
also highly positive for viral replication [45,77,78]. In
addition, the level of human cell engraftment in other
organs is also sufficient to sustain detectable HIV-1
replication, including the bone marrow [56,67,72], lungs
[43,45,67,77], small intestines [45,55,67], large intestines
[45,78], male reproductive tract [45], and female repro-
ductive tract [45,67,77]. One recent study has shown
that human macrophages can be detected in hNSG
brains and that systemic infection with HIV-1 leads to
detection of p24
+ cells in the hNSG brain [75]. The dis-
tribution of engrafted cells and HIV-1 replication in
HSC-engrafted humanized mice is impressive and indi-
cates that these models are superior to the previous
SCID-hu thy/liv and SCID-hu PBL models in terms of
penetration of the graft into various tissues, accompa-
nied by the ability of HIV-1 to traffic to and replicate in
various sites. As expected, CCR5 tropic strains are lar-
gely unable to replicate in the humanized mouse thymus
due to the immature, CCR5-negative status of human
thymocytes [44,86]. When the identity of p24
+ cells has
been analyzed, most cells have been shown to be CD4
+
T cells although infected CD68
+ macrophages have also
been detected [44,72].
CD4
+ T cell loss occurs in blood, lymphoid organs, and
gut-associated lymphoid tissue
CD4
+ T cell loss in the blood occurs in every HSC-
engrafted model and with nearly every virus strain ana-
lyzed to date. Loss occurs regardless of the route of
infection, including mucosal transmission. In one case,
CCR5-tropic HIV-1 failed to deplete in the hNOG
model through 6 weeks of infection [43], but all other
studies using strain JR-CSF have shown successful loss
[42,45,49,51,59] unless antiviral strategies were
employed. Gorantla et al.s h o w e dal a c ko fC D 4
+ Tc e l l
l o s sw i t haC C R 5t r o p i cp r i m a r yi s o l a t e( s u b t y p eC
strain 1157), but it is unclear what time point was ana-
lyzed, and if animals were monitored long enough to
detect loss with a CCR5-using strain [46]. It is also pos-
sible that CD4
+ T cell rebound (see below) had occurred
at the time point analyzed.
Some reports with mutated virus strains have shown
an inability to deplete helper T cells levels. However,
the study of mutant viral strains in humanized mice is
still underdeveloped when the large body of mutant
viruses examined in tissue culture is considered. Our
f i r s tr e p o r ti nR A G - h um i c es h o w e dal a c ko fC D 4
+ T
cell loss in the blood through 24 weeks of infection with
NLENG1-IRES, a reporter strain of HIV-1 that expresses
GFP and places the nef gene under the control of an
IRES element in the background of the CXCR4-tropic
strain NL4-3 [87]. In this virus, nef gene expression is
not under the control of the native viral promoter, and
gene function may be attenuated. Two mice were
reported [57], but follow-up work with an additional 3
mice gave the same result (unpublished). Viremia was
readily detectable in these mice, but the lack of T cell
loss may indicate that attenuation of nef gene expression
in HIV-1 is able to prevent viral pathogenesis and AIDS.
Interestingly, no differences in viremia have been noted
between animals infected with NL4-3 and NLENG1-
IRES, suggesting that viral replication occurs in similar
fashion regardless of nef gene status, but that patterns of
CD4
+ T cell loss in the blood may be different.
Another study with a lethal vif mutation in the CCR5
tropic JR-CSF background showed an inability to repli-
cate or to cause CD4
+ T cell depletion in hNOG mice;
this finding was likely due to increased susceptibility of
the virus to human APOBEC proteins which are nor-
mally targeted for degradation by vif [73]. HIV-1 vif is
known to promote destruction of human APOBEC3G in
vitro,b u tin vivo studies were needed to confirm the
relevance. hNOG mice were infected with either wild-
type virus or a vif-deficient strain and hypermutations
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APOBEC proteins were detected specifically in cells
infected by the vif-deficient strain. Together, these
reports provide evidence that targeting of specific HIV-1
proteins for mutation or silencing can either block virus
replication or virus-induced pathogenesis.
As mentioned above, CD4
+ T cell loss in blood is both
more rapid and more severe with CXCR4-virus or dual-
tropic virus. However, CD4
+ T cell rebound has been
shown to occur in some studies, with CCR5-virus
[23,43,44,53,55,57,58] or CXCR4-virus [23,44,55,57] or
dual-tropic virus [49]. Other reports have failed to
detect CD4
+ T cell rebound, with most using CCR5-
virus [46,67,74,77,78] and two using CXCR4-virus
[45,67]. The mechanism for CD4
+ T cell rebound is cur-
rently unclear, but this rebound has been seen in some
studies that track infection for at least several months.
Immune responses are one possible reason, but murine
adaptive immunity is absent, and human anti-HIV-1
adaptive immunity is not thought to be very strong in
most HSC-engrafted models (see below). The drop in
CD4
+ T cells is accompanied by a drop in viremia, and
this decrease in total virus levels may explain the ability
of helper T cells to rebound. Direct routes of infection
(intraperitoneal or intravenous) give similar results for
CD4
+ T cell loss, while limited data on mucosal trans-
mission indicate that slower and less severe loss occurs
[45,55,77].
CD4
+ T cell loss in the blood and lymphoid organs do
not always correlate with one another. Several groups
have examined CD4
+ T cell levels in primary and sec-
ondary lymphoid organs of HSC-humanized mice in
order to determine the extent of CD4
+ T cell loss.
Zhang et al.s h o w e dl o s so fC D 4
+ T cells by FACS ana-
lysis in the lymph nodes and thymus of RAG-hu mice
infected with dual-tropic virus by FACS staining, with
CCR5 tropic virus unable to deplete CD4
+ thymocytes.
Severe loss of CD4
+CD8
+ thymocytes was seen with
dual-tropic virus [49]. Jiang et al. reported that regula-
tory helper T cells are specifically depleted in spleen
and mesenteric lymph nodes relative to other types of
helper T cells early during infection of RAG-hu mice by
FACS analysis [61]. Our group showed that CD4
+ thy-
mocytes are depleted in large areas of the RAG-hu thy-
mus following infection by CXCR4-tropic virus by
immuno-staining [57]. Sun et al. showed intrarectal
HIV-1 transmission which was accompanied by an over-
all decrease in hematoxylin and eosin-stained cells in
t h et h y m i co r g a n o i da n ds m a l la n dl a r g ei n t e s t i n e si n
mice infected with a CXCR4-tropic strain [45]. They
also used FACS staining to show CD4
+ Tc e l ll o s si n
the bone marrow, thymic organoid, spleen, peripheral
and mesenteric lymph nodes, liver, lung, and small and
large intestines with either CXCR4-virus [45] or CCR5-
virus [77]. The extensive loss of helper T cells in the
gut-associated lymphoid tissue (GALT) is comparable to
human AIDS patients and indicates that BLT mice, and
possibly other strains of HSC-humanized mice, are a
useful model to study HIV-1 pathogenesis associated
with GALT infection.
Mechanisms of HIV-1 pathogenesis
Due to the lack of appropriate in vivo models required
to study HIV-1-mediated pathogenesis, there are still
many unanswered questions about how HIV-1 infection
leads to AIDS. Several research groups have begun to
analyze the mechanisms of HIV-1-mediated pathogen-
esis in HSC-humanized mice, and it is clear that at least
some mechanisms proposed to take place in humans
also occur in HSC-humanized mice [51,61,63,72,
75,76,80]. A summary of mechanisms of HIV-1 patho-
genesis explored to date in humanized mice is found in
Table 2.
A hallmark of AIDS is chronic immune activation, and
specific infection and depletion of regulatory T cells (T-
regs), which normally suppress chronic immune cell
activation, could play a critical role in this process. Jiang
et al.r e p o r t e dt h a tC D 4
+FoxP3
+ T-regs develop in
RAG-hu mice. These T-regs migrate to all lymphoid
organs and are functional in that they can suppress pro-
liferation of other T cells. T-regs are preferentially
infected and depleted in vivo in RAG-hu mice as com-
pared to other types of human T cells; both the CCR5
tropic JR-CSF and the dual-tropic HIV-R3A exhibited
the increased rate of infection. Specific depletion of T-
regs was largely due to apoptosis. Depletion of T-regs
by administration of denileukin diftitox led to reduced
viral replication as measured by viral load and presence
of p24
+ cells [61].
Depletion of effector memory T cells may lead to
exhaustion of the central memory T cell pool, which has
been postulated to play a role in progression to AIDS
[88]. Nie et al. examined the effects of HIV-1 infection
on memory T cell populations in hNOG mice [72].
They showed that while CXCR4 tropic HIV-1 is able to
deplete both naïve and memory T cells in hNOG mice,
CCR5 tropic HIV-1 selectively depletes effector memory
T cells. Similar findings with CCR5 tropic virus were
seen in the small intestines in infected BLT mice [77].
Infected effector memory T cells in humanized mice are
predominantly activated and proliferating [72,77], similar
to findings in human AIDS patients [89,90] and SIV
+
non-human primates [91,92]. Brainard et al. similarly
found an increase in activated CD4
+ and CD8
+ T cells
(Ki-67
+ or CD27
-) in HIV-1-infected BLT mice [42].
While central memory T cells are CCR5
- and are not
infected by CCR5-tropic HIV-1, these cells serve as an
important reservoir for replenishment of both the
Berges and Rowan Retrovirology 2011, 8:65
http://www.retrovirology.com/content/8/1/65
Page 7 of 19central memory and effector memory T cell populations
[93].
Pathogenesis of HIV-1 has been implicated to be due
to immune depletion in the GALT, and increased trans-
location of bacteria or bacterial products such as lipopo-
lysaccharide (LPS) may lead to enhanced immune
activation and AIDS. HIV-1
+ humans and SIV
+ sooty
mangabeys have higher levels of LPS in the bloodstream
than uninfected controls, and it was hypothesized that
LPS translocated across the gut [94]. HIV-1
+ RAG-hu
mice also exhibit increased levels of bacterial LPS in the
bloodstream [51]. This was shown to be specific to
HIV-1 infection, since treatment with a chemical that
induces intestinal permeability did not result in higher
LPS in the blood [51]. These experiments illustrate the
utility of humanized mice to further investigate preli-
minary findings in humans and non-human primates. In
addition, HIV-1
+ RAG-hu mice showed increased levels
of activated CD8
+ T cells whether or not high levels of
LPS were detected in the plasma [51]. Increased num-
bers of activated CD8
+ T cells in HIV-1
+ mice were cor-
related with enhanced CD4
+ T cell inversion [51].
Two studies have shown that CD8
+ T cells respond to
HIV-1 infection in similar fashion as seen in humans.
Sato et al.s h o w e dt h a ti nH I V - 1 - i n f e c t e dh N O Gm i c e
t h em e m o r yC D 8
+ population preferentially expands
while the naïve population remains constant [66]. Sun et
al.d e m o n s t r a t e dt h a ti nH I V - 1
+ BLT mice, the fre-
quency of CD8
+CXCR4
+ cells in the mesenteric lymph
nodes and GALT decreased while the CD8
+CCR5
+
population expanded. Overall, CD8
+ T cells expanded in
the GALT and mesenteric lymph nodes and most of
these cells had an effector memory phenotype (CD27
-
CD45RA
-) [45]. Taken together, these findings indicate
that HIV-1 induces a state of generalized immune acti-
vation in the gut lymphoid tissues, similar to findings in
humans [89].
Human macrophages can be detected in the hNSG
brain at 26 weeks post-engraftment after intrahepatic
injection of human HSCs into newborns [75]. Animals
were not perfused in this report, and this makes inter-
pretation of these findings difficult, since blood cells
may be detected in perivascular spaces. However, subse-
quent work by the same group showed limited histologi-
cal data from perfused animals providing evidence for
human cell engraftment in the meninges and perivascu-
lar spaces [76]. Further, intraperitoneal injection of
CCR5 tropic HIV-1 leads to detection of low numbers
of p24
+ cells in the hNSG brain (non-perfused samples)
[75], possibly due to similar mechanisms of HIV-1 entry
into the human brain which is thought to take place via
trafficking of infected monocytes [95]. Meningitis,
meningoencephalitis, and neuroinflammation were
detected in a subset of animals [75]. The frequency and
severity of these symptoms were increased in animals
depleted of human CD8
+ T cells, indicating that the
human immune response may be able to at least par-
tially control neuro-invasion or neuropathogenesis in
humanized mice [75]. Follow-up work by the same
group has shown detection of brain abnormalities speci-
fically in HIV-1
+ humanized mice as detected by live
animal imaging and post-mortem immuno-staining [76].
They concluded that systemic HIV-1 infection leads to a
disruption of the normal humanized mouse brain archi-
tecture [76]. As methods to improve mouse humaniza-
tion continue to evolve, we expect that penetration of
human immune cells to the brain will also likely
increase; accompanied by higher levels of neuro-
Table 2 Mechanisms of HIV-1 pathogenesis in the new generation of humanized mice
Mouse Model/HIV-1 strain Finding Reference
RAG-hu mice; R5 tropic JR-CSF
and dual-tropic R3A
CD4
+FoxP3
+ T regulatory cells are preferentially infected and depleted in spleen and lymph nodes;
depletion occurs via apoptosis.
[61]
hNOG mice; R5 tropic JR-CSF or
X4 tropic NL4-3
X4 tropic virus depletes both naïve and memory T cells, while R5 tropic virus selectively depletes
effector memory T cells (CD45RO
+CD45RA
-).
[72]
BLT mice; R5 tropic JR-CSF R5 tropic virus depletes CD4
+ effector memory T cells (CD45RA
-CD27
-) in small intestines [77]
RAG-hu mice; R5 tropic YU-2 R5 tropic virus leads to translocation of LPS to the plasma, resulting in CD8 T cell activation, lower
CD4 T cell ratios, and higher viral loads.
[51]
hNOG mice; R5 tropic ADA Human macrophages, microglia, and dendritic cells are engrafted in the meninges and perivascular
spaces in the hNOG brain. p24+ cells can be detected in the brain following intraperitoneal
infection. Human immune cells infiltrate regions of viral replication in the brain, and CD8 T cell
depletion leads to meningitis and encephalitis.
[75]
hNOG mice;R5 tropic ADA HIV-1 infection leads to structural changes in brain architecture, leading to loss of neuronal integrity. [76]
RAG-hu mice; dual-tropic R3A Plasmacytoid dendritic cells (pDC) are productively infected and activated during early HIV infection,
leading to CD4 T cell activation and apoptosis. pDC levels were stable, but function was impaired in
the spleen and bone marrow.
[63]
BLT mice; NL4-3 backbone with
LAI env gene
Virus with a single amino acid substitution in env (V38E) has similar viral load to virus with wild-type
env, but is attenuated for CD4 T cell depletion due to a defect in caspase-dependent bystander
apoptosis.
[80]
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studies of the mode of viral penetration of the brain as
well as pathologies associated with HIV-1 brain infec-
tion, and may additionally be useful to develop new
methods to block neuro-invasion by HIV-1.
Zhang et al. recently showed that productive HIV-1
infection leads to activation of human plasmacytoid den-
dritic cells (pDCs) in the spleen and bone marrow of
RAG-hu mice [63]. Activation of pDCs was followed by an
increased rate of activation and apoptosis in CD4
+ Tc e l l
populations. Normal pDC levels were maintained despite
infection of these cells, but the functionality of these cells
was impaired as measured by IFN-a production and the
ability to respond to TLR7 and TLR9 agonists [63].
The mechanisms by which HIV-1 induces CD4
+ T cell
depletion and AIDS are not fully understood [93]. Garg
et al. have recently shown that a point mutation in
HIV-1 gp41 (V38E) that alters cell-to-cell fusion activity
of HIV-1 envelope has no effect on the ability of the
virus to replicate in BLT mice, as measured by plasma
antigenemia [80]. However, CD4
+ T cell depletion was
significantly reduced in mice infected with the V38E
strain at later time points. The authors present evidence
that caspase-dependent bystander apoptosis was efficient
with wild-type virus, but attenuated in V38E virus.
An area of viral pathogenesis that has yet to be explored
in humanized mice is the effect of secondary infections by
bacterial, viral, and fungal pathogens which contribute fre-
quently to AIDS-related mortality. Some pathogens asso-
ciated with complications in AIDS patients, such as the
herpesviruses EBV, KSHV and CMV as well as hepatitis B
and C viruses have already been characterized for infection
in humanized mice. A summary of these agents, as well as
the humanized mouse models they have been studied in
and appropriate references is found in Table 1.
In summary, HSC-humanized mice produce a large vari-
ety of human T cell types, and HIV-1 targets various sub-
populations of these cells similarly to what is seen in
humans. Further, HIV-1 is able to penetrate into the
GALT and possibly into the brain, which are major sites of
AIDS pathogenesis. The ability to produce large numbers
of humanized mice and at a relatively inexpensive cost will
allow for further expansion of our understanding of how
HIV-1 penetrates these organs and how organ function is
compromised by infection. While we are still in an explora-
tory phase of determining whether or not humanized mice
truly recapitulate human AIDS pathogenesis, we look for-
ward to the future when novel discoveries will be made in
humanized mice and then confirmed in human patients.
Human immune responses against HIV-1 in humanized
mice
One of the most exciting developments of HSC-huma-
nized mice is the capacity to develop human primary
immune responses against specific agents. However,
human adaptive immune responses in HSC-engrafted
mice directed towards HIV-1 have been somewhat dis-
appointing thus far; the reasons for this finding are not
well understood. It appears that the ability to generate
immune responses against HIV-1 may be fundamentally
different than against other agents, because human
immune responses against other antigens tend to be
readily detectable in terms of both frequency and
potency, such as after challenge with EBV [17,27-30],
KSHV [32], HSV-2 [34], or Dengue virus [35,96] or
after vaccination with H. influenzae B conjugate vaccine
[46], tetanus toxin [17,97], or Hepatitis B Virus surface
antigen [97]. This is generally not the case for HIV-1
(see below). Following is a summary of what has been
reported in the literature in regards to human immune
responses to HIV-1 in humanized mice.
Baenziger et al. reported a frequency of only 1 in 25
RAG-hu mice with detectable human antibodies against
HIV-1 [44], Gorantla et al. reported 0 of 17 in RAG-hu
mice [46], and our unpublished results were similar (0
of 16 in RAG-hu). Sango et al. reported detection of
human IgG specific to HIV-1 gp120 and Gag in RAG-
hu mice, but the frequency was not reported [64]. Wata-
nabe et al. demonstrated human antibody responses
a g a i n s tH I V - 1i n3o f1 4h N O Gm i c e[ 4 3 ] ,a n dS a t oet
al.f o u n dt h es a m ei n2o f7h N O Gm i c e[ 6 6 ] .T h e
Watanabe report showed that antibodies targeted either
gp120 or p24 antigens [43]. In contrast, Brainard et al.
reported that 9 of 9 BLT mice had detectable anti-HIV-
1 human antibodies after 12 weeks of infection. It is
interesting to note that no responses were detected in
BLT until after 5 weeks post-infection, and that 10
weeks were required for a majority to seroconvert [42].
A separate report showed detection of human IgG spe-
cific to HIV-1 proteins by western blot in 3 of 4 intrar-
ectally-infected BLT mice [45]. A slow humoral
response has also been shown against Dengue viral
infection of RAG-hu mice, wherein the earliest humoral
responses were detected at 2 weeks (1 of 10 animals
assayed), 3 of 8 were positive by 6 weeks, and all 8 of 8
were positive by 8 weeks [35]. Baenziger et al.m e n -
tioned that testing was only performed on samples that
were at least 3 weeks post-infection, and that the lone
positive sample was from 6 weeks post-infection. Thus,
it is possible that testing was performed too early to
detect animals that would later become positive. How-
ever, our own unpublished ELISA testing has included
at least 6 RAG-hu animals through 21 weeks (all nega-
tive) and so a slowly developing response is not likely
t h ed i f f e r e n c eb e t w e e nt h eR A G - h ua n dB L Tm o d e l s .
However, these results should be viewed in light of
many variables that exist between the above studies,
including the use of cord blood or fetal liver samples for
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used to infect animals, the time points after engraftment
at which infection took place and when samples were
collected for serology, and the methodologies used to
detect antibody responses. We feel that the amount of
data currently available is insufficient to make definite
conclusions about which models may be superior (if
any) for analyzing anti-HIV-1 antibody responses.
Follow-up work with Dengue virus in RAG-hu mice
has shown that ~40-60% of RAG-hu animals produce
human anti-Dengue antibodies, depending upon the
experiment (n > 50 infected animals). Thus, it is likely
that there are fundamental differences in the antibody
responses to different agents in humanized mice and
that more rapid and profound T cell depletion asso-
ciated with HIV-1 infection in humanized mice likely
plays a role in weak antibody responses against HIV-1
as compared to more robust responses seen in humans
and in humanized mice to other antigens. Interestingly,
Sango et al. reported detection of gp120- and Gag-spe-
cific IgM and IgG in RAG-hu mice and evidence is pre-
sented that intrasplenic injection of HIV-1 results in an
increased frequency of anti-HIV-1 antibody responses as
compared to intravenous or intraperitoneal infection
[64]. Since only the mean O.D. reading of an ELISA test
is reported, the frequency of these responses is unclear,
and additionally the sample sizes were small for this
experiment (n = 6 for intrasplenic injection, but only n
= 2 for intravenous and intraperitoneal injection as con-
trols). However, there was a clear correlation between
the number of infected splenocytes and enhanced anti-
HIV-1 antibody production. Nevertheless, these data are
promising that RAG-hu mice are capable of producing
strong anti-HIV-1 antibody responses, and we look for-
ward to seeing if anti-HIV-1 T cell responses will also
be detectable after intrasplenic infection.
Brainard et al. reported in the BLT model that ELI-
SPOT assays could detect human IFN-g production
from T cells in response to HIV-1 peptides in 4 of 6
mice, representing two different human tissue donors.
No in vivo responses were detected earlier than 9 weeks
post-infection, and gag and nef peptides were common
targets, as seen in humans [98]. Intracellular cytokine
staining assays further confirmed the ELISPOT results
a n ds h o w e dt h a tb o t hC D 4
+ and CD8
+ T cells reacted
to produce IFN-g [42]. A similar report by Gorantla et
al. showed specific T cell responses by both CD4
+ and
CD8
+ T cells to gag (but only weak, if at all, to env) in
hNSG mice [71]. These reports mark the best evidence
to date that HSC-engrafted mice can produce T cell
responses against HIV-1, although as mentioned above
these models can be used to study T cell responses
against a variety of other viral pathogens. A similar
study conducted by An et al. in RAG-hu mice failed to
detect T cell responses using a similar ELISPOT assay
for detection of responses against gag and nef [58].
Anti-HIV-1 T cell responses have not been reported to
date in the RAG-hu model, although 4 animals were
also tested by Baenziger et al. [44]. The mechanisms for
any true differences seen in human immune responses
between different humanized mouse models are not yet
clear, but it has been hypothesized that the presence of
human thymic tissue grafts in BLT mice may provide a
more appropriate stromal environment for human T
cell selection [42] and the available data support this
idea for HIV-1 infections. However, detection of anti-
HIV-1 T cell responses in other models that lack
human thymic stromal cells (hNSG, hNOG, and RAG-
h um i c e )t oE B V ,H C V ,a n do t h e ri m m u n o g e n s
[17,28,29,37,47] would argue that a stromal environment
is not necessary to generate human T cell responses in
general in humanized mice, suggesting a unique prop-
erty of HIV-1.
HIV-1 vaccines have yet to be tested in humanized
mice. A major advantage of this system is that animals
can be exposed to virus by various routes and then
tested for sterilizing immunity to the virus. However,
since human adaptive immune responses to the virus
are weak it is likely that improvements in the potency of
the immune system against HIV-1 will need to be made
before vaccine efficacy studies will be plausible. How-
ever, if the mechanism for weak immune responses is in
fact due to rapid helper T cell loss, then it is possible
that vaccines may elicit stronger responses than the live
virus itself due to presentation of antigen without
accompanying helper T cell loss.
A recent report by O’Connell et al.h a ss h o w nt h a t
human T cells can be expanded in RAG-hu mice by
introduction of hIL-7 via lentiviral gene transfer. T cells
formed a larger percentage of human leukocytes, and
similar proportions of CD4
+ and CD8
+ T cells were
found in hIL-7 expressing mice as compared to control
animals. Although it is possible that hIL-7 administra-
tion may lead to enhanced cellular immunity, the func-
tionality of T cell responses were not examined in this
report. Total serum IgM levels increased in hIL-7 trea-
ted animals, although the capacity to mount specific
antibody responses to ovalbumin or HIV-1 did not
change. Although levels of viremia were not statistically
different in hIL-7 expressing mice, the total number of
human T cells remained high in the spleen despite sys-
temic HIV-1 infection [52]. These data indicate that IL-
7 should be further explored as a possible mechanism
to restore T cell levels in HIV-1 patients without
increasing viral load. These interesting results may also
lead to an improved model of humanized mice, possibly
one in which anti-HIV-1 T cell responses will be more
robust.
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humanized mice. The virus uses many mechanisms to
hide in the host, but integrated provirus in a transcrip-
tionally repressed state in resting memory T cells
(reviewed in [99]) and extracellular virions tethered to
the surface of follicular dendritic cells [100] contribute
extensively to the latent reservoir. These models could
be useful to discover new ways to induce an exit from
latency as we move towards finding a cure for HIV-1.
Anti-HIV-1 drug testing in humanized mice
Several anti-HIV-1 drugs have been tested for efficacy in
HSC-engrafted mice, using both the RAG-hu and BLT
models. In some reports, the effects of targeted drugs
on a previously established HIV-1 infection were studied
and in other reports the ability of antiviral drugs to pre-
vent infection were analyzed. Some studies have
employed FDA-approved drugs such as emtricitabine +
tenofovir disoproxil fumarate (RT inhibitors) or AZT +
lamivudine + indinavir (2 RT inhibitors + protease inhi-
bitor, respectively) [77,78], or emtricitabine + tenofovir
disoproxil fumarate plus an experimental strand transfer
inhibitor (L-870812) [59]. The most recent study to
examine the effects of drugs on a pre-existing infection
has employed an experimental TAT peptide inhibitor
which blocks the interaction of cellular cdk2 with the
TAR element [50] and is currently being studied in
humans [101].
Denton et al. have published two reports on pre-expo-
sure prophylaxis in BLT mice using vaginal [77], rectal
[78], or intravenous [78] exposure to HIV-1. In the vagi-
nal challenge report, emtricitabine + tenofovir disoproxil
fumarate (RT inhibitors) were administered orally 2
days prior to challenge, 3 hours prior to challenge, and
4 days post-challenge. 5 of 5 animals receiving drugs
were entirely protected from infection with a CCR5 tro-
pic strain, while 7 of 8 control animals became infected
[77]. Successful HIV-1 replication in challenged mice in
both of the Denton et al. reports was assayed by a wide
variety of parameters including plasma viral load, pro-
viral DNA amplification, plasma antigenemia, FACS
staining to detect CD4
+ T cell loss, and in situ hybridi-
zation. Thus, this initial study has provided evidence
that clinicians should administer anti-retrovirals to
women who are at a high risk of HIV-1 infection via
vaginal intercourse. In the second Denton et al.r e p o r t ,
the ability of RT inhibitors to prevent rectal and intrave-
nous transmission was examined [78]. In this study the
same RT inhibitors were used; in this case the drugs
were administered for seven consecutive days and with
exposure to HIV-1 on the third day. 9 of 9 animals rect-
ally exposed receiving drugs were entirely protected
from infection with a CCR5 tropic strain, while 12 of 19
control animals became infected. This experiment is
similar in nature to a recent clinical trial testing these
same drugs (Truvada) as a pre-exposure regimen
designed to test for protection against HIV-1 transmis-
sion in men who have sex with men or transgender
women who have sex with men. That study showed that
oral administration of Truvada resulted in a 44% reduc-
tion in HIV-1 transmission [102]. Although Denton et
al. used intraperitoneal injection of Truvada versus oral
administration in the clinical trial, the results are very
promising that humanized mice can be useful to per-
form pre-clinical testing. The reasons for the differences
in protection rates between the two studies are not
clear, but the increased levels of human target cells in
mucosal tissues in humans vs. humanized mice and the
possible presence of other sexually transmitted diseases
in human patients may contribute to lower protection
rates in humans. Intravenous challenge with HIV-1 was
performed in an identical time frame as in the rectal
and vaginal challenge experiments outlined above. In
this case, 7 of 8 mice administered drugs were protected
from infection, while 6 of 6 control mice were infected.
T h el o n ea n i m a lt ob e c o m ei n f e c t e dd i dn o te x h i b i tR T
mutations that would explain enhanced susceptibility to
the virus. In addition, when 4 animals were infected
intravenously followed by a 7-day regimen of drugs
beginning 24 hours after exposure, all animals became
infected but with delayed kinetics [78].
Neff et al. have shown that oral administration of
either raltegravir (integrase inhibitor) or maraviroc
(CCR5 entry inhibitor) prevents vaginal transmission of
HIV-1 in RAG-hu mice. Protection rates were measured
by attempts to detect viral RNA or DNA in the blood
and by monitoring of CD4
+ T cell counts in the periph-
eral blood. 6 of 6 RAG-hu mice were protected from
transmission with each drug, while 8 of 8 control mice
were infected [62]. Taken together, these reports are
very promising for effectivep r e v e n t i o no fH I V - 1t r a n s -
mission in humans for various routes of viral exposure.
In the other three reports, the effects of anti-HIV-1
drugs on a previously established infection were ana-
lyzed. Choudhary et al. showed that a combination of
the RT inhibitors emtricitabine, tenofovir disoproxil
fumarate, and an experimental strand transfer inhibitor
(L-870812) was able to both reduce viral load as well as
to rescue from CD4
+ T cell loss when administration
was begun 10-20 days after intravenous infection of
RAG-hu mice with JR-CSF (dose of virus not reported).
Although limited numbers of animals were used in
these experiments, it is notable that viremia was still
detectable at most time points during the drug adminis-
t r a t i o np h a s e .U p o nd i s c o n t i n u a t i o no ft h ed r u g s ,v i r e -
mia rebounded, and CD4
+ T cell levels once again
dropped [59]. This finding demonstrates that viable
virus was indeed present despite administration of
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of known resistance mutations developed in 2 of 6 mice
and viral rebound occurred; this finding is discussed
further in the section of viral evolution (see below).
Sango et al. administered a classical HAART cocktail
of AZT + lamivudine + indinavir beginning 1 week after
intrasplenic infection (dose range of 800 to 8000
TCID50) of RAG-hu mice with strain JR-CSF [64]. They
found a nearly 300-fold reduction in the number of
infected splenocytes which was accompanied by a 300-
fold decrease in viremia. CD4
+ T cell loss was almost
entirely prevented as well. The Choudhary et al.a n d
Sango et al. reports clearly demonstrate that administra-
tion of anti-retroviral drugs in RAG-hu mice results in a
decrease in viral load and prevention of [64] or rescue
from [59] CD4+ T cell loss. However, it is important to
note that both studies have utilized time points of drug
administration that are considerably earlier than those
used in humans, where detection of seroconversion
rarely happens in the range of 7-20 days.
Van Duyne et al. studied the effects of cdk2 inhibitors
that prevent interaction with the TAR element in RAG-
hu mice [50]. Their data showed that some experimental
peptide inhibitors were able to lower viremia to levels
comparable to those achieved by AZT. It is interesting
to note that proviral DNA copy number appeared to be
substantially higher in peptide inhibitor-treated mice as
compared to AZT-treated mice (about 6 × higher) and
somewhat higher even than untreated HIV
+ mice (nearly
2 × higher). However, no statistical analysis was pro-
vided and only single time points were analyzed, so it is
unclear if the difference was significant. The ramifica-
tions of possibly increasing proviral load due to inhibi-
tion of viral gene expression are not clear. This type of
study shows the utility of humanized mice to identify
potential complications before use in humans and to
explore the mechanisms and possible side effects.
Luo et al. have recently shown that administration of
the highly neutralizing human monoclonal antibody
2G12 is effective at reducing viremia in HIV-infected
RAG-hu mice. This report also showed that an engi-
neered 2G12 dimer was more stable and had greater
viral inhibition than the monomeric form [53]. Antibo-
dies were either administered in purified form, or via
“backpack tumors” into CD34-engrafted mice. While
intravenous challenge with HIV-1 in immunized mice
still resulted in successful viral transmission, viral loads
were suppressed. The mechanism of action of these
antibodies has not yet been examined, but subtle aspects
of humanized mouse engraftment are important to con-
sider. RAG-hu mice are not expected to produce human
complement since production predominantly takes place
in liver cells; human liver cells are not present in RAG-
hu mice. Human NK cells are also not effectively
produced in humanized mice unless human IL-15 is
administered [103,104]. Complement-mediated lysis of
virions and complement and NK cell-mediated lysis of
infected cells may thus be defective in this system when
human antibodies are administered. These studies
would indicate that human monoclonal antibodies may
be another option for administration to HIV
+ patients
to prevent progression to AIDS, especially since many
patients fail to develop neutralizing antibodies on their
own.
Taken together, these studies show that both FDA-
approved and experimental treatments can be effective
at blocking HIV-1 replication and helper T cell loss in
humanized mice. In addition, the rationale for adminis-
tration of anti-HIV-1 drugs to humans who are at high
risk for HIV-1 exposure has been strengthened. Thus,
humanized mice represent an important model to test
unproven anti-HIV-1 drugs and proven drugs for new
applications.
Anti-HIV-1 gene therapy testing in humanized mice
Gene therapy represents a novel method to prevent and/
or treat HIV-1 infections at multiple levels of the viral
life cycle [104,105]. Current work in the anti-HIV-1
gene therapy field includes such strategies as blocking
viral entry, blocking viral gene expression or expression
of host cell factors needed for entry or replication by
RNA interference [106], production of neutralizing anti-
bodies against HIV-1, introduction of specific antiviral
genes such as the APOBEC family of cytosine deami-
nases [107] and TRIM5a [108], and the targeting of
these potential therapies to specific cell types and/or to
hematopoietic stem cells [109]. Lentiviral vectors, ironi-
cally based upon the HIV-1 genome itself, have been
extensively studied as gene delivery vehicles to human
hematopoietic cells including HSCs [110]. These vectors
are capable of genomic integration and long-term gene
delivery, and do not appear to be accompanied by the
leukemic events that can occur with oncoretroviruses
[111]. A host of clinical trials are already underway to
test various novel gene therapeutic strategies to control
HIV-1 infection [112].
Gene therapy of HSCs holds high promise for a life-
long infection such as with HIV-1 because gene-modi-
fied stem cells have the potential to produce HIV-1-
resistant progeny cells for long periods after initiation of
therapy. Continual production of HIV-1-resistant pro-
geny cells has the potential to provide a selective event
wherein a reservoir of resistant helper T cells are main-
tained; thus development of A I D Sm a yb ei n d e f i n i t e l y
delayed [113]. Since HSCs are used to engraft the latest
generation of humanized mice, it is only natural that
several reports have emerged in which the human HSCs
have been gene-modified prior to engraftment. However,
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gene therapy poses a greater risk due to previous experi-
ence with oncoretroviral gene therapy of humans with
SCID, as noted above. Thus, many efforts are also direc-
ted at modification of mature human T cells and mono-
cytes despite the fact that these modified cells will
naturally deplete during the lifetime of a patient. A sum-
mary of strategies tested thus far in the new generation
of humanized mice is found in Table 3.
In 2008, Ter Brake et al. used an established lentiviral
vector to express an shRNA targeting the nef gene
sequence by transducing HSCs prior to engraftment to
produce RAG-hu mice [60]. While no in vivo challenges
were performed in this study, they did show that gene-
modified HSCs can still engraft in immunodeficient
mice and that multi-lineage hematopoiesis still occurs.
It is interesting to note that while transduction efficien-
cies were similar between the shRNA vector and a con-
trol vector only expressing GFP, the level of engrafted
cells containing the shRNA vector was significantly
lower than cells containing the control vector. This find-
ing indicates that high level expression of shRNAs in
human HSCs may interfere with engraftment and/or
hematopoiesis. When RAG-hu derived cells were
infected ex vivo, substantial protection from HIV-1
infection was noted preferentially in cells receiving the
shRNA vector. Taken together with our results with
NLENG1-IRES (see above) [57], these findings suggest
that nef is a candidate target to block viral replication
and cell death.
Joseph et al. used a lentiviral vector to deliver the
gene encoding a highly neutralizing anti-HIV-1 human
monoclonal antibody (2G12) into HSCs, followed by
engraftment into hNOG mice [68]. They also found suc-
cessful engraftment, followed by secretion of the 2G12
antibody. Upon challenge with HIV-1, viremia in gene
therapy-treated hNOG mice was found to be 70-fold
lower as compared to untreated animals and the num-
ber of HIV
+ splenocytes was reduced 200-fold. Since
many HIV
+ patients fail to produce neutralizing antibo-
dies this method may be useful to boost immunity in
those already infected.
Recent success with possibly curing a human patient
of HIV-1 infection via a bone marrow transplantation
using homozygous CCR5Δ32 donor cells [114] has gen-
erated renewed interest in finding ways to interfere with
CCR5 expression, especially since no known immunolo-
gical defects are associated with the Δ32 allele. Various
gene therapy strategies are currently being investigated
as a novel method to treat HIV
+ patients by manipulat-
ing cells to downregulate CCR5 expression in order to
possibly prevent progression to AIDS by protecting cells
that would normally be susceptible to the virus. Such a
strategy was employed by Holt et al. using zinc-finger
Table 3 Gene therapeutic strategies used to control HIV-1 infection in the new generation of humanized mice
Humanized
mouse model
Strategy Findings Reference
RAG-hu mice Lentiviral vector transduction of HSCs with anti-nef
shRNA construct
Lentivirally-transduced HSCs can engraft in RAG-hu mice. Ex
vivo challenge with HIV-1 showed preferential protection of
transduced cells.
[60]
hNOG mice Lentiviral vector transduction of HSCs with gene
encoding neutralizing human antibody to HIV-1 (2G12)
Lentivirally-transduced HSCs can engraft in hNOG mice.
Antibody was produced; viremia was ~70-fold reduced and
number of infected splenocytes was reduced ~200-fold.
[68]
hNOG mice Disrupt CCR5 gene in HSCs by zinc finger nucleases ~17% of all alleles in the HSC population were gene
modified; engraftment was still successful. Gene-modified cells
were positively selected during HIV-1 infection.
[74]
BLT mice Targeted delivery of an anti-CCR5 siRNA to human
lymphocytes in vivo
CCR5 expression was silenced and plasma viral load was
decreased ~30-fold relative to controls. No CD4 T cell
depletion noted through 55 days.
[81]
BLT mice Lentiviral transduction of HSCs with anti-CCR5 shRNA
construct
CCR5 expression was silenced in a variety of cell types and
tissue sites. Protection against infection was measured ex vivo.
[79]
RAG-hu mice RNA-based aptamers used to neutralize virus and/or to
deliver anti-tat/rev siRNA to infected cells
Viral load decreased relative to controls; helper T cell
depletion blocked. Combination therapy more effective than
aptamer alone.
[54]
hNOG mice Targeting of siRNAs to block expression of CD4, CCR5,
or viral RNAs to mature human T cells
Viral load was lower after treatment, despite a moderate and
transient effect on receptor knockdown. CD4 T cell levels
preserved.
[69]
hNOG mice Lentiviral vector transduction of HSCs to express
antisense RNA to env
Only a low percentage of cells were transduced (4-11%); no
effect on viral load; virus mutated targeted env sequences.
[70]
hNOG mice Lentiviral transduction of mature CD4 T cells to
produce viral entry inhibitor
Transduced cells expressing entry inhibitor expanded relative
to non-transduced or control transduced cells, indicating
protection.
[125]
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HSCs, followed by transplantation into hNOG mice
[74]. Transplantation efficiency was not affected by ZFN
treatment, and genetically modified cells were positively
selected after HIV-1 challenge, despite a relatively low
level of successful gene targeting (estimated at 17% of
total CCR5 alleles disrupted, with a lower level of cells
having biallelic disruption). Viremia levels were lower
and human T cells persisted at higher levels, indicating
that the strategy was effective. Shimizu, et al reported
that the BLT model can also be used to produce gene-
modified cells using a lentiviral vector to transduce
HSCs [79]. Their strategy was to target the cellular co-
receptor CCR5 by delivery of a construct encoding a
shRNA, and they showed successful knockdown of the
cellular gene in T cells and monocytes/macrophages and
in a variety of lymphoid tissues and also the GALT. Pro-
tection against HIV-1 challenge was again shown, but
only ex vivo. CCR5 represents an excellent target for
HIV-1 gene therapy because while viral genes can read-
ily mutate to escape from therapy, cellular genes do not
readily mutate.
Neff et al. recently reported on testing a novel anti-
HIV-1 drug in RAG-hu mice [54]. They used RNA-
based aptamers to target HIV-1 gp120, either alone or
conjugated to an anti-tat/rev siRNA designed to block
early viral gene expression in infected cells. The aptamer
binds to gp120 on virions and neutralizes infectivity of
particles, but can also bind to gp120 on the surface of
infected cells. In conjunction with the antiviral siRNA
the aptamer can be used to target delivery of the siRNA
payload directly to infected cells. Their results showed
that use of the aptamer alone or the aptamer-siRNA
combination resulted in a drop in HIV-1 viremia by
multiple logs, and that helper T cell levels were pre-
served. Further, the aptamer-siRNA combination pro-
vided a longer effect as compared to the aptamer alone,
indicating that viral replication was inhibited.
Some studies have been performed wherein gene ther-
apy was performed on mature human blood cells in
humanized mice. Kim et al. targeted nanoparticles to a
lymphocyte-specific marker in BLT mice; nanoparticles
carried an anti-CCR5 siRNA which was accompanied by
s i l e n c i n go fC C R 5e xpression for at least 10 days [81].
Although treated mice still developed a productive
infection with HIV-1, the mean plasma viral load was
decreased about 30-fold relative to control vector-trans-
duced mice and no CD4
+ T cell loss was noted in trea-
ted mice for up to 55 days while CD4
+ T cell loss was
detected with the control vector.
Kumar et al. delivered siRNAs to mature T cells in
hNOG mice using a single-chain antibody to target CD7
+ cells [69]. siRNA targets included either CD4, CCR5, a
combination of siRNAs to HIV-1 vif and tat,o ra
combination targeting CCR5+vif+tat.U s i n gP B L sf o r
transplantation, they showed that CD4 could be effec-
tively downregulated by siRNA targeting. This resulted
in lower levels of detectable HIV-1 p24 following ex
vivo infection. Targeting of CCR5 was highly effective at
reducing p24 levels in the blood in PBL-engrafted mice
at day 5 post-infection, while p24 levels rose to within 1
log of the control vector by 13 days post-infection indi-
cating that CCR5 downregulation was transient. CD4
+ T
cell loss in treated animals was mild compared to ani-
mals receiving the control siRNA. The triple combina-
tion of CCR5+vif+tat siRNAs was highly effective at
blocking virus replication for both days 5 and 13. CD4
knockdown was moderate after intravenous injection of
the siRNA (~50% by FACS staining) and CCR5 knock-
down was also moderate (~66% by Q-RT-PCR). Ex vivo
infection of cells with CCR5 knockdown exhibited HIV-
1 replication at about 50% levels as compared to the
control vector. Viremia was highly suppressed by siR-
NAs against vif and tat,a n dC D 4
+ T cell loss was lar-
gely prevented by the same.
HIV-1 evolution in humanized mice
Evolution of HIV-1 in vivo allows the virus to escape
from selective pressures including antiviral drugs and
host immune responses. In addition, evolution of the
env gene to change from the use of CCR5 as a co-recep-
tor to use of CXCR4 is correlated with faster progres-
sion to AIDS [115,116]. The ability to recapitulate the
process of viral evolution in humanized mice would
allow for development of models that could potentially
predict what would take place in humans. Choudhary et
al. examined the effects of a combination of anti-HIV-1
drugs targeting reverse transcriptase (tenofovir diso-
proxil fumarate and emtricitabine) and the strand trans-
fer inhibitor L-870812 in HIV-infected RAG-hu mice
[59]. They found that 2 of 6 animals developed known
resistance mutations in reverse transcriptase or inte-
grase, with resistance becoming detectable as early as 1
month post-infection. Two animals died prematurely; so
the incidence of drug resistance mutations may be
higher.
A recent study has focused on human APOBEC pro-
teins and their ability to induce hypermutations in the
H I V - 1g e n o m ei nh N O Gm i c e[ 7 3 ] .A n i m a l sw e r e
infected with the molecular clones JR-CSF or vif-defi-
cient JR-CSF, however vif-deficient virus was unable to
replicate as assessed by undetectable RNA viral load,
provirus, and p24
+ cells in spleen. Subsequently, sequen-
cing analysis focused on the pol region were performed
on samples obtained from animals infected with wild-
type virus. It was found that G-to-A mutations in pro-
viral DNA were significantly more common than other
types of mutations in the HIV-1 genomes of infected
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active in vivo against wild-type HIV-1. By way of con-
trast, G-to-A mutations were less common in plasma
RNA sequences as compared to proviral sequences, indi-
cating that hypermutated genomes were less fit for
replication.
RAG-hu mice were infected with the CCR5 tropic
molecular clone JR-CSF and analyzed for mutations in
the env gene for up to 44 weeks post-infection without
selective pressures from drugs or RNA silencing [65]. As
mentioned above, anti-HIV-1 immune responses in
RAG-hu mice have been low to undetectable and thus
the selective pressure of the host immune response was
likely weak in this study. Nonetheless, the mean rate of
divergence of HIV-1 in RAG-hu mice was found to be
similar to what was seen in human cohorts during a
similar time period [117,118]. Several mutations were
found in common across the group of infected mice,
and included the loss of glycosylation sites and substitu-
tions in the CD4 binding site. One animal developed
env variants that exhibited the ability to use CXCR4 as a
co-receptor, despite being infected with a molecular
clone known to use CCR5 as a co-receptor. This data
provide evidence that the transition from usage of CCR5
to CXCR4 is indeed as a result of viral mutation and not
due to transmission of CXCR4-using viruses which can
emerge later during infection [118].
The SCID-hu-PBL mouse model was used extensively
to test anti-HIV-1 strategies and yielded much data
[119]. A recent report using hNOG mice similarly
humanized with mature human PBMCs analyzed a strat-
egy currently under investigation in humans in which an
antisense payload targeting env is introduced via adop-
tive T-cell therapy [70]. Previous reports have shown
that HIV-1 can readily escape from RNA silencing
[120], and this was found to be the case in humanized
mice when env is targeted [70].
In a similar adaptation of the SCID-hu-PBL model,
Mukherjee et al. performed an experiment to parallel a
clinical trial experiment wherein an anti-HIV-1 env anti-
sense RNA was introduced into PBMC-humanized
hNOG mice via a lentiviral vector [70]. However, HIV-1
had already been shown to mutate in response to this
antisense RNA and so the purpose of these experiments
was more to examine development of these mutations
in an animal system. Human T cells were transduced
with the vector prior to engraftment, although only
moderate levels of transduced cells were used (~4-11%)
in order to mirror the clinical trial where only a low
transduction efficiency is currently feasible. Animals
were then challenged with o n eo ft w oH I V - 1s t r a i n s ;
NL4-3 (CXCR4 tropic) with a 100% match with the env
target sequence and an NL4-3 derivative expressing the
BaL envelope (CCR5 tropic) and hence a mismatched
env target sequence. As expected, no differences in viral
titer were detected since only a low percentage of T
cells were transduced. Pyrosequencing of individual viral
genomes was performed and sequences were analyzed
relative to input viral sequences. Enriched A-to-G tran-
sitions were detected in the env target sequence region
in animals receiving the antisense payload, as were viral
g e n o m i cd e l e t i o n si nt h es a m er e g i o n .T h e s ef i n d i n g s
were in accordance with previous work done using the
same vector in a human T cell line in tissue culture
[121]. G-to-A transitions also occurred at a high rate,
but these changes were likely due to APOBEC-induced
mutations (see below). Interestingly, for reasons which
are still unclear the increase in env mutations was only
noted in animals challenged with the CCR5-tropic
envelope strain, despite the antisense RNA being imper-
fectly matched with the target sequence.
Conclusions
There are many areas of HIV-1 biology that are still
poorly understood, including the mechanisms by which
HIV-1 causes AIDS and why some patients fail to
develop AIDS. We have yet to produce a vaccine that
can effectively prevent infection; nor do we have anti-
viral drugs that can cure an infection or that are fully
refractory to viral resistance. The major roadblock to
most of these unresolved problems has been the lack of
suitable animal models in which to study them. The
new generation of humanized mice is the most physiolo-
gically relevant system to date that allows for direct stu-
dies of HIV-1 itself as it interacts with human hemato-
lymphoid cells in a complex three-dimensional environ-
ment. Humanized mice are relatively inexpensive to pro-
duce, can be worked with under conditions that are
available at many institutions, and produce many aspects
of HIV-induced pathogenesis directly on human cells;
none of these factors apply to non-human primate
research. The biggest hurdle yet to be overcome is to
refine the models so that human adaptive immune
responses are more robust so that vaccine efficacy
experiments can be performed. Nevertheless, the data
that have been generated in less than five years since
the initial reports of HIV-1 infection in these new mod-
els provide much optimism that humanized mice will be
useful to answer many of these unsolved questions and
problems.
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